1. P1125: CELESTIMO: A PHASE III TRIAL EVALUATING THE EFFICACY AND SAFETY OF MOSUNETUZUMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA. (23rd June 2022) Authors: Nastoupil, L.; Morschhauser, F.; Scholz, C. W.; Bishton, M.; Yoon, S.-S.; Giri, P.; Wei, M. C.; Knapp, A.; Li, C.-C.; Bottos, A.; Li, H.; Purev, E.; Bartlett, N. L. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1015 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗